Alcohol-Related Disorders Market and Epidemiology Forecast, 2024-2034, Featuring Analysis of Vivitrol (Alkermes), DCR-AUD (Dicerna Pharmaceuticals) and Other Drugs


Dublin, June 06, 2024 (GLOBE NEWSWIRE) -- The "Alcohol-Related Disorders Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034" report has been added to ResearchAndMarkets.com's offering.

The 7 major alcohol-related disorders markets reached a value of US$ 667.4 Million in 2023. Looking forward, the 7MM are expected to reach US$ 1,628.6 Million by 2034, exhibiting a growth rate (CAGR) of 10.42% during 2023-2034.

The increasing prevalence of various associated risk factors, such as depression, anxiety, bipolar disorder, adverse childhood experiences like abuse and neglect, social and peer influences, etc., is primarily driving the alcohol-related disorders market. In addition to this, the rising incidence of genetic variations in enzymes that are involved in alcohol metabolism, neurotransmitter systems, and reward pathways, which can influence how the body processes and responds to alcohol, is creating a positive outlook for the market. Moreover, the inflating application of various medications, such as naltrexone, acamprosate, disulfiram, etc., to reduce cravings, discourage alcohol consumption, and assist in maintaining sobriety is further bolstering the market growth.

Apart from this, the escalating adoption of several behavioral therapies, including cognitive-behavioral therapy (CBT), that aid patients in identifying and modifying maladaptive thoughts and behaviors related to alcohol use is acting as another significant growth-inducing factor. Additionally, the emerging popularity of relapse prevention strategies, since they help to identify triggers, manage cravings, and develop healthy coping mechanisms to prevent relapse, is expected to drive the market during the alcohol-related disorders forecast period.

Report Scope

This report provides an exhaustive analysis of the alcohol-related disorders market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for alcohol-related disorders and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report.

Time Period of the Study

  • Base Year: 2023
  • Historical Period: 2018-2023
  • Market Forecast: 2024-2034

Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan

Analysis Covered Across Each Country

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the alcohol-related disorders market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the alcohol-related disorders market

Competitive Landscape

This report also provides a detailed analysis of the current alcohol-related disorders marketed drugs and late-stage pipeline drugs.

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance

Key Questions Answered in this Report

Market Insights

  • How has the alcohol-related disorders market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
  • What was the country-wise size of the alcohol-related disorders market across the seven major markets in 2023 and what will it look like in 2034?
  • What is the growth rate of the alcohol-related disorders market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the market?

Epidemiology Insights

  • What is the number of prevalent cases (2018-2034) of alcohol-related disorders across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of alcohol-related disorders by age across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of alcohol-related disorders by gender across the seven major markets?
  • How many patients are diagnosed (2018-2034) with alcohol-related disorders across the seven major markets?
  • What is the size of the alcohol-related disorders patient pool (2018-2023) across the seven major markets?
  • What would be the forecasted patient pool (2024-2034) across the seven major markets?
  • What are the key factors driving the epidemiological trend of alcohol-related disorders?
  • What will be the growth rate of patients across the seven major markets?

Alcohol-Related Disorders: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current marketed drugs and what are their market performance?
  • What are the key pipeline drugs and how are they expected to perform in the coming years?
  • How safe are the current marketed drugs and what are their efficacies?
  • How safe are the late-stage pipeline drugs and what are their efficacies?
  • What are the current treatment guidelines for alcohol-related disorders drugs across the seven major markets?
  • Who are the key companies in the market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the alcohol-related disorders market?
  • What are the key regulatory events related to the alcohol-related disorders market?
  • What is the structure of clinical trial landscape by status related to the alcohol-related disorders market?
  • What is the structure of clinical trial landscape by phase related to the alcohol-related disorders market?
  • What is the structure of clinical trial landscape by route of administration related to the alcohol-related disorders market?

Key Attributes

Report AttributeDetails
No. of Pages135
Forecast Period2023-2034
Estimated Market Value (USD) in 2023$667.4 Million
Forecasted Market Value (USD) by 2034$1628.6 Million
Compound Annual Growth Rate8.4%
Regions CoveredGlobal

Key Topics Covered

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Alcohol-Related Disorders - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 Alcohol-Related Disorders - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Alcohol-Related Disorders - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.3 Epidemiology Scenario - United States
7.4 Epidemiology Scenario - Germany
7.5 Epidemiology Scenario - France
7.6 Epidemiology Scenario - United Kingdom
7.7 Epidemiology Scenario - Italy
7.8 Epidemiology Scenario - Spain
7.9 Epidemiology Scenario - Japan

8 Alcohol-Related Disorders - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Alcohol-Related Disorders - Unmet Needs

10 Alcohol-Related Disorders - Key Endpoints of Treatment

11 Alcohol-Related Disorders - Marketed Products
11.1 List of Alcohol-Related Disorders Marketed Drugs Across the Top 7 Markets
11.1.1 Vivitrol (Naltrexone controlled-release) - Alkermes
11.1.2 Campral (Acamprosate calcium) - Forest Pharmaceuticals

12 Alcohol-Related Disorders - Pipeline Drugs
12.1 List of Alcohol-Related Disorders Pipeline Drugs Across the Top 7 Markets
12.1.1 DCR-AUD - Dicerna Pharmaceuticals
12.1.2 Psilocybin - Clairvoyant Therapeutics
12.1.3 BPL-003 - Beckley Psytech Limited
12.1.4 ASP8062 - Astellas Pharma
12.1.5 Arbaclofen Placarbil - Indivior Inc

13. Alcohol-Related Disorders - Attribute Analysis of Key Marketed and Pipeline Drugs

14. Alcohol-Related Disorders - Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Alcohol-Related Disorders - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.3 Market Scenario - United States
15.4 Market Scenario - Germany
15.5 Market Scenario - France
15.6 Market Scenario - United Kingdom
15.7 Market Scenario - Italy
15.8 Market Scenario - Spain
15.9 Market Scenario - Japan

16 Alcohol-Related Disorders - Recent Events and Inputs From Key Opinion Leaders

17 Alcohol-Related Disorders Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 Alcohol-Related Disorders Market - Strategic Recommendations

19 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/nzds2q

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

 
Alcohol-Related Disorders Market

Contact Data